Friday 6 November 2026 Export TXG’s income statement to Excel — free account

10x Genomics

TXG Healthcare Medical Devices

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.

Revenue: +1.12%
EPS: +31.8%
Free cash flow: −4.61%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

57.68 0.38 −0.65%

Follow TXG

Alert me

Market cap: $7.6B
P/E: 0.0×
Fwd P/E: −95.9×
Dividend yield: —
F-score: 6/9
Altman Z: 3.99
Beneish M: −3.23
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

10x Genomics 10-Q filed Aug 8, 2024

Fiscal Q2 2024 · Period ended Jun 30, 2024 · Filed Aug 8, 2024 · accepted 4:12 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov